(NASDAQ: BDTX) Black Diamond Therapeutics's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 37.5%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 10.08%.
Black Diamond Therapeutics's revenue in 2024 is $0.On average, 1 Wall Street analysts forecast BDTX's revenue for 2025 to be $136,017,943, with the lowest BDTX revenue forecast at $136,017,943, and the highest BDTX revenue forecast at $136,017,943. On average, 2 Wall Street analysts forecast BDTX's revenue for 2026 to be $1,172,185,048, with the lowest BDTX revenue forecast at $1,006,946,520, and the highest BDTX revenue forecast at $1,337,423,575.
In 2027, BDTX is forecast to generate $1,888,528,974 in revenue, with the lowest revenue forecast at $672,332,037 and the highest revenue forecast at $3,614,560,467.